ClinicalTrials.gg
RecruitingNCT04755387Updated Oct 1, 2025

Ticagrelor De-escalation Strategy in AMI Patients

A Phase 4 interventional study of De-escalation strategy and Conventional strategy in Acute Myocardial Infarction, sponsored by Dong-A University. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by Dong-A University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,312
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Myocardial Infarction with a site in Korea, Republic of — 21 open to participants now, 26 under way, 5 of them phase 3. Myocardial Infarction · Korea, Republic of.

Planned enrollment
28th of 73
2,312 · median 820
Started
2023
with 3 others
Phase 4
22 of 99
4 open now
Primary completion
2027-01
later than 8 of 25 live
Registered
69th of 99
by date
Lead sponsor
3 of 99
Dong-A University

Among the 99 studies in Myocardial Infarction with a site in Korea, Republic of, this one is the 28th largest by planned enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2023, is one of 22 in phase 4, reaches primary completion later than 8 of the 25 other live ones, and was the 69th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

21 of the 99 studies in Myocardial Infarction with a site in Korea, Republic of are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Myocardial Infarction with a site in Korea, Republic of, or all of them as a file.
02

Study summary

DAPT de-escalation strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y12 inhibitor at conventional doses to either clopidogrel or reduced-dose prasugrel) or abbreviation of DAPT duration. The EASTYLE trial will evaluate a hybrid DAPT de-escalation strategy (reduced-dose ticagrelor, followed by aspirin early discontinuation) in AMI patients, compared with a conventional DAPT strategy.

Read the detailed description

In ACS patients undergoing percutaneous coronary intervention, conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y12 inhibitor (prasugrel or ticagrelor) for 12 months. Although this approach reduces ischaemic risk, patients are exposed to a substantial risk of bleeding during the stabilized period. Strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y12 inhibitor at conventional doses to either clopidogrel or reduced-dose prasugrel) or abbreviation of DAPT duration. Abbreviation of DAPT duration after 1-6 months, followed by monotherapy with aspirin or a P2Y12 inhibitor, reduces bleeding without an increase in ischaemic events in patients at high bleeding risk, particularly those without high ischaemic risk. Either strategy requires assessment of the ischaemic and bleeding risks of each individual. Previous clinical and laboratory evidence demonstrates that a conventional-dose of ticagrelor has a potent antiplatelet effect, which appears to have a potential to increase the risk of bleeding during the stabilized period. Adjunctive use of aspirin to P2Y12 inhibitor would be important to protect the risk of thrombotic events in AMI patients, which use has a limited benefit with increased bleeding rate during the the stabilized period.

The EASTYLE trial will evaluate clinical benefit of step-down de-escalation DAPT strategy including downgrading of P2Y12 inhibition (from 90 mg to 60 mg ticagrelor at 1 month post-PCI) and abbreviation of DAPT duration (aspirin discontinuation at 3 months post-PCI), compared with a conventional DAPT strategy in AMI patients. This trial will support that the optimal platelet inhibition would be attenuated over time even in AMI patients. The result will make a big step toward precision medicine in the field of antiplatelet treatment in AMI patients.

03

Conditions studied

  • Acute Myocardial Infarction

Keywords

  • Ticagrelor
  • DAPT
  • De-escalation strategy
  • Abbreviated strategy
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis with acute myocardial infarction.
  • Age ≥19 year-old
  • Successful PCI with ultrathin bioresorbable polymer sirolimus-eluting stents (Orsiro; Biotronik AG).
  • Provision of .

Exclusion criteria

Exclusion Criteria:

  • Any prior event of hemorrhagic stroke or ICH.
  • Active bleeding (e.g., GI bleeding, ICH) or high-risk of serious bleeding.
  • Bleeding diathesis or coagulopathy (e.g., ≤ 10 g/dL or count \< 100,000/μL, bleeding needing transfusion within 30 days, and so on).
  • Allergy to stent metal, contrat media, and antiplatelet regimens.
  • Moderate to severe hepatic dysfunction ( class B or C).
  • Need for oral anticoagulation therapy.
  • Current or potential pregnancy.
  • Currently treated with strong inhibitors.
  • \<1 year.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,312 participants (estimated)

Study arms

  • Experimental
    De-escalation strategy

    PCI \~ 1 month: ticagrelor 90 mg twice daily + aspirin 100 mg once daily 1 \~ 3 months: ticagrelor 60 mg twice daily + aspirin 100 mg once daily 3 \~ 12 months: ticagrelor 60 mg twice daily

    Drug: De-escalation strategy

  • Active comparator
    Conventional strategy

    PCI \~ 12 months: ticagrelor 90 mg twice daily + aspirin 100 mg once daily

    Drug: Conventional strategy

Interventions

  • DrugDe-escalation strategy

    De-escalation strategy indicates conventional DAPT (ticagrelor 90 mg twice daily + aspirin 100 mg once daily) for 1 month, followed by de-escalation DAPT (ticagrelor 60 mg twice daily + aspirin 100 mg once daily) between 1 and 3 months. Between 3 and 12 months, patients will be treated with ticagrelor monotherapy (ticagrelor 60 mg twice daily).

    Also known as: Ticagrelor 60 mg, aspirin early discontinuation

  • DrugConventional strategy

    Conventional stratetgy indicates conventional DAPT including ticagrelor 90 mg twice daily and aspirin 100 mg once daily during 12 months.

    Also known as: Ticagrelor 90 mg, DAPT

06

What researchers measure

Primary outcomes

  1. Primary endpoint (NACE)

    MACCE (all-cause death, non-fatal myocardial infarction, stent thrombosis or non-fatal stroke) + major bleeding (BARC type 2, 3, or 5 bleeding)

    Time frame: 12 months

Secondary outcomes

  1. Major adverse cardiac and cerebrovascular events (MACCE)

    all-cause death, non-fatal myocardial infarction, stent thrombosis or non-fatal stroke

    Time frame: 12 months

  2. Bleeding events

    BARC type 2, 3 or 5 bleeding; BARC 3 or 5 bleeding; TIMI major or minor bleeding; GUSTO severe or moderate bleeding; ISTH major bleeding

    Time frame: 12 months

  3. All-cause death

    any mortality

    Time frame: 12 months

  4. CV death

    Death related CV system

    Time frame: 12 months

  5. MI

    Myocardial infarction

    Time frame: 12 months

  6. Stent thrombosis

    definite or probable stent thrombosis by Academic Research Consortium (ARC) definition

    Time frame: 12 months

  7. Ischemic stroke

    Stroke

    Time frame: 12 months

  8. Cardiac death, or MI

    Coronary thrombotic events

    Time frame: 12 months

  9. Cardiac death, MI or stent thrombosis

    Coronary thrombotic events

    Time frame: 12 months

  10. Cardiovascular death, MI or stroke

    MACE

    Time frame: 12 months

  11. TLR

    target lesion revascularization

    Time frame: 12 months

  12. TVR

    target vessel revascularization

    Time frame: 12 months

  13. Any revascularization

    Re-PCI during follow-up

    Time frame: 12 months

Other outcomes

  1. Type of AMI

    STEMI vs. NSTEMI

    Time frame: 12 months

  2. HBR

    presence of HBR (high bleeding risk) criteria

    Time frame: 12 months

  3. DM

    presence of diabetes mellitus

    Time frame: 12 months

  4. CKD

    presence of chronic kidney disease

    Time frame: 12 months

  5. Anemia

    presence of anemia

    Time frame: 12 months

  6. Gender

    Male vs. female

    Time frame: 12 months

  7. Age

    Old vs. young age (65 yo, 75 yo)

    Time frame: 12 months

  8. Complex PCI

    Presence of complex PCI

    Time frame: 12 months

  9. GDMT

    Presence of guideline-directed medical therapy

    Time frame: 12 months

  10. Type of statin

    Rosuvastatin vs. other statins

    Time frame: 12 months

  11. CHF

    Presence of congestive heart failure

    Time frame: 12 months

  12. PAD

    Presence of peripheral artery disease

    Time frame: 12 months

  13. PFT

    VerifyNow assy

    Time frame: 12 months

  14. Predictors of MACCE

    Clinical impact of de-esclation strategy on MACCE

    Time frame: 12 months

  15. Predictors of maor bleeding

    Clinical impact of de-esclation strategy on major bleeding

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • DongA University Hospital
    Busan, 602-715, South Korea
    Recruiting
    • Moo Hyun Kim, M.D. · Contactkimmh@dau.ac.kr · +82-51-240-2976
    • Moo Hyun Kim, M.D. · Principal investigator
08

References and documents

Publications

  • Goto S, Huang CH, Park SJ, Emanuelsson H, Kimura T. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. Circ J. 2015;79(11):2452-60. doi: 10.1253/circj.CJ-15-0112. Epub 2015 Sep 16. PubMed 26376600 ↗
  • Jin C, Kim MH, Bang J, Serebruany V. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study. Cardiology. 2017;138(4):201-206. doi: 10.1159/000478000. Epub 2017 Aug 16. PubMed 28810251 ↗
  • Gorog DA, Ferreiro JL, Ahrens I, Ako J, Geisler T, Halvorsen S, Huber K, Jeong YH, Navarese EP, Rubboli A, Sibbing D, Siller-Matula JM, Storey RF, Tan JWC, Ten Berg JM, Valgimigli M, Vandenbriele C, Lip GYH. De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis. Nat Rev Cardiol. 2023 Dec;20(12):830-844. doi: 10.1038/s41569-023-00901-2. Epub 2023 Jul 20. PubMed 37474795 ↗
  • Gorog DA, Jeyalan V, Markides RIL, Navarese EP, Jeong YH, Farag M. Comparison of De-escalation of DAPT Intensity or Duration in East Asian and Western Patients with ACS Undergoing PCI: A Systematic Review and Meta-analysis. Thromb Haemost. 2023 Aug;123(8):773-792. doi: 10.1055/s-0043-57030. Epub 2023 Apr 18. PubMed 37072035 ↗
  • Kang MG, Ahn JH, Kim K, Koh JS, Park JR, Hwang SJ, Park Y, Tantry US, Gurbel PA, Hwang JY, Jeong YH. Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in East Asian patients with acute coronary syndrome. Front Cardiovasc Med. 2022 Dec 12;9:1053867. doi: 10.3389/fcvm.2022.1053867. eCollection 2022. PubMed 36578832 ↗
  • Kubica J, Adamski P, Gorog DA, Kubica A, Jilma B, Budaj A, Siller-Matula JM, Gurbel PA, Alexopoulos D, Badariene J, Dabrowski P, Dudek D, Giannitsis E, Horszczaruk G, Jaguszewski MJ, James S, Jeong YH, Kryjak M, Niezgoda P, Ostrowska M, Patti G, Romanek J, Di Somma S, Specchia G, Tantry U, Gasior M, Tycinska A, Wojakowski W, Buszko K, Gil R, Gruchala M, Kasprzak J, Kleinrok A, Legutko J, Lesiak M, Navarese EP. Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. Cardiol J. 2022;29(1):148-153. doi: 10.5603/CJ.a2021.0118. Epub 2021 Oct 8. No abstract available. PubMed 34622433 ↗
  • Kim L, Choe JC, Ahn JH, Lee HW, Oh JH, Choi JH, Lee HC, Cha KS, Hong TJ, Jeong YH, Park JS. Temporal Trends of Bleeding Episodes during Half- vs. Standard-Dose Ticagrelor in Acute Coronary Syndrome Patients with Low Platelet Reactivity: A Randomized BLEEDING-ACS Trial. J Clin Med. 2021 Mar 10;10(6):1159. doi: 10.3390/jcm10061159. PubMed 33802015 ↗
  • Kim HK, Tantry US, Smith SC Jr, Jeong MH, Park SJ, Kim MH, Lim DS, Shin ES, Park DW, Huo Y, Chen SL, Bo Z, Goto S, Kimura T, Yasuda S, Chen WJ, Chan M, Aradi D, Geisler T, Gorog DA, Sibbing D, Lip GYH, Angiolillo DJ, Gurbel PA, Jeong YH. The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. Thromb Haemost. 2021 Apr;121(4):422-432. doi: 10.1055/s-0040-1718729. Epub 2020 Nov 10. PubMed 33171520 ↗
  • Park Y, Koh JS, Lee JH, Park JH, Shin ES, Oh JH, Chun W, Lee SY, Bae JW, Kim JS, Kim W, Suh JW, Yang DH, Hong YJ, Chan MY, Kang MG, Park HW, Hwang SJ, Hwang JY, Ahn JH, Choi SW, Jeong YH; HEALING-AMI Investigators. Effect of Ticagrelor on Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction (HEALING-AMI). JACC Cardiovasc Interv. 2020 Oct 12;13(19):2220-2234. doi: 10.1016/j.jcin.2020.08.007. PubMed 33032710 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Jan 2027, 45 months after the start.

Of 83 non-industry phase 4 interventional studies under Myocardial Infarction, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 78. This study's planned 45 months is close to that.

Counting every sponsor, half of 87 studies reached it within 42 months; a quarter within 22 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2021
First posted
Feb 16, 2021
StartActual
Mar 27, 2023
Primary completionEst.
Jan 15, 2027
CompletionEst.
Jan 31, 2028
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04755387
Lead sponsor
Dong-A University
Collaborators
Biotronik SE & Co. KG, Samjin Pharmaceutical Co., Ltd.
Responsible party
Moo Hyun Kim (Professor, Deptartment of Cardiology, Dong-A University Hospital, Dong-A University) — Principal investigator
First posted
Feb 16, 2021
Start date
Mar 27, 2023
Primary completion
Jan 15, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Oct 1, 2025

Study contacts

Moo Hyun Kim, MD, PhD
Contact
kimmh@dau.ac.kr
+82-51-240-2976
Young-Hoon Jeong, MD, PhD
Contact
goodoctor@naver.com
+82-2-2610-6795
Moo Hyun Kim, MD, PhD
principal investigator · Dong-A University Hospital, Busan, Republic of Korea

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion